Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II DEVEC metronomic chemotherapy study in elderly non-fit patients with aggressive B-cell lymphoma
2016-003703-62Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide, etoposide, vinorelbine, prednisone and rituximab in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Complete response. Started Oct 2021; status: completed.
02
Drugs
cyclophosphamideetoposidevinorelbineprednisonerituximab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on 2016-003703-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003703-62.